Nasdaq:US$16.94 (-0.01) | HKEX:HK$26.65 (-0.20) | AIM:£2.80 (+0.02)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab  in Patients with Advanced Solid Tumors